TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03714555

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.
“Study was closed due to low subject enrollment at site.”

The sponsor’s own words in the registry.

Life of this trial

2018201920202021202220232024Registered2018-10-09Started2019-10-17Primary completion2020-07-22Stopped2020-07-29Results posted2023-10-18

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
HonorHealth Research Institute
Sponsor type
University, hospital or other
Conditions
Metastatic Pancreatic Cancer
Interventions
Safety Laboratories; AE Assessment; Physical Exam; Concomitant Medication Review; Tumor Imaging; nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Participants
1
Sites
1
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.